Lilly Targets Aduhelm With Aggressive Plans For Donanemab In Alzheimer’s
Lilly plans a head-to-head study of donanemab versus Biogen’s Aduhelm to see which clears amyloid plaque better and has begun a rolling BLA toward accelerated approval of the Alzheimer’s drug.
You may also be interested in...
Phase III results for Eisai/Biogen’s lecanemab are the main event at the Clinical Trials on Alzheimer’s Disease meeting, but other data – even Roche’s failed Phase III gantenerumab studies – also may have implications for the amyloid-clearing antibody.
The pharma is increasing its manufacturing capacity for tirzepatide, mindful of its potential in a second indication of obesity and the supply issues faced by competitor Novo Nordisk.
With Lilly’s sales narrative hampered by global price pressures, Lilly CEO David Ricks again criticized drug price negotiation proposals before Congress. Mounjaro launch offers a bright spot, exceeding projections.